Vamorolone治疗DMD显示剂量相关肌肉功能改善
本研究为开放标签、多剂量递增研究,纳入48名4-<7岁未用激素的DMD男孩,口服Vamorolone 0.25、0.75、2.0、6.0 mg/kg/d各12例,主要目标确定最佳剂量,主要疗效终点为从仰卧位站起速度。24周治疗显示所有剂量安全耐受,2.0 mg/kg/d组肌肉功能改善,且骨形成标志物骨钙素升高,肾上腺抑制和胰岛素抵抗标志物低于激素治疗研究,提示2.0和6.0 mg/kg/d可能有效。
要点
- Vamorolone 2.0 mg/kg/d可改善DMD男孩从仰卧位站起速度。
- 24周治疗中所有测试剂量安全耐受,未出现多数糖皮质激素不良反应。
- 骨钙素升高提示可能减少激素相关骨病变。
核心结论
- 每日Vamorolone治疗在2.0和6.0 mg/kg/d剂量下显示出可能疗效,基于24周开放标签探索性研究。
研究设计与样本
- 开放标签、多剂量递增研究,纳入48名4-<7岁未用激素的DMD男孩。
- 剂量水平为0.25、0.75、2.0、6.0 mg/kg/d口服混悬液,每个剂量12例。
- 主要目标为确定Vamorolone最佳剂量,主要疗效终点为从仰卧位站起速度。
主要发现
- 所有测试剂量口服Vamorolone在24周治疗期间安全且耐受良好。
- 2.0 mg/kg/d剂量组达到主要疗效终点,即肌肉功能改善(从仰卧位站起,24周Vamorolone治疗 vs 自然历史对照)。
- 骨形成标志物骨钙素在Vamorolone治疗男孩中升高,提示可能减少糖皮质激素相关骨病变。
- 肾上腺抑制和胰岛素抵抗的生物标志物结果在Vamorolone治疗DMD患者中低于已发表的糖皮质激素治疗研究。
关键数值与推荐
- 剂量水平为0.25、0.75、2.0、6.0 mg/kg/d,相当于DMD中糖皮质激素剂量的三分之一至十倍。
- 主要疗效终点为从仰卧位站起速度,2.0 mg/kg/d组在24周时达到改善。
临床怎么用
- 对于4-<7岁未用激素的DMD男孩,Vamorolone 2.0 mg/kg/d可能作为改善肌肉功能的选项,且耐受性良好。
- 治疗中可关注骨钙素升高及肾上腺抑制、胰岛素抵抗标志物较低,可能减少激素相关不良反应。
局限性
- 研究为开放标签、探索性、24周设计,证据等级为Class IV。
- 样本量较小,每个剂量组仅12例。
- 疗效比较基于自然历史对照,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study vamorolone, a first-in-class steroidal anti-inflammatory drug, in Duchenne muscular dystrophy (DMD). METHODS: An open-label, multiple-ascending-dose study of vamorolone was conducted in 48 boys with DMD (age 4-<7 years, steroid-naive). Dose levels were 0.25, 0.75, 2.0, and 6.0 mg/kg/d in an oral suspension formulation (12 boys per dose level; one-third to 10 times the glucocorticoid dose in DMD). The primary goal was to define optimal doses of vamorolone. The primary outcome for clinical efficacy was time to stand from supine velocity. RESULTS: Oral administration of vamorolone at all doses tested was safe and well tolerated over the 24-week treatment period. The 2.0-mg/kg/d dose group met the primary efficacy outcome of improved muscle function (time to stand; 24 weeks of vamorolone treatment vs natural history controls), without evidence of most adverse effects of glucocorticoids. A biomarker of bone formation, osteocalcin, increased in vamorolone-treated boys, suggesting possible loss of bone morbidities seen with glucocorticoids. Biomarker outcomes for adrenal suppression and insulin resistance were also lower in vamorolone-treated patients with DMD relative to published studies of glucocorticoid therapy. CONCLUSIONS: Daily vamorolone treatment suggested efficacy at doses of 2.0 and 6.0 mg/kg/d in an exploratory 24-week open-label study. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for boys with DMD, vamorolone demonstrated possible efficacy compared to a natural history cohort of glucocorticoid-naive patients and appeared to be tolerated.
引用
- Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019. PMID: 31451516. doi:10.1212/WNL.0000000000008168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。